Citations

Clear

9383 citation(s) found for "Thomas, PS".

Prevention of Alveolar Destruction and Airspace Enlargement in a Mouse Model of Pulmonary Lymphangioleiomyomatosis (LAM)
Goncharova, Elena A. , Goncharov, Dmitry A. , Fehrenbach, Melane, Khavin, Irene, Ducka, Blerina, Hino, Okio , Colby, Thomas V. , Merrilees, Mervyn J., Haczku, Angela , Albelda, Steven Μ. , Krymskaya, Vera P.

Mayo Clinic

Science Translational Medicine | October 3, 2012 | Volume: 4 | Issue: 154 | Pages: No page available

10.1126/scitranslmed.3003840 | PMID 23035046 Get It

In a mouse model of the human disease pulmonary lymphangioleiomyomatosis, treatment with rapamycin plus simvastatin prevented alveolar space enlargement and growth of TSC2-null lesions.
Update for Pathologists on Idiopathic Interstitial Pneumonias
Larsen, Brandon T. , Colby, Thomas V.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | September 30, 2012 | Volume: 136 | Issue: 10 | Pages: 1234-1241

10.5858/arpa.2012-0225-ra | PMID 23020729 Get It

Context.—Idiopathic interstitial pneumonias are a subset of diffuse pulmonary interstitial diseases classified by international consensus in 2002 as idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, respiratory bronchiolitis interstitial lung disease, desquamative interstitial pneumonia, and lymphoid interstitial pneumonia. Each is associated with a characteristic histopathologic pattern. In 2011, updated consensus guidelines were released for diagnosis and management of idiopathic pulmonary fibrosis. The entire group of idiopathic interstitial pneumonias is currently undergoing refinement, with updates expected in a forthcoming consensus classification. Many of these recent and anticipated changes are relevant to pathologists. Objectives.—To review international consensus guidelines for diagnosis of idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias and to discuss recent and expected future classification updates. Data Sources.—Published peer-reviewed literature and personal experience of the authors. Conclusions.—Diagnosis of idiopathic interstitial pneumonias by multidisciplinary discussion among clinicians, radiologists, and pathologists is now strongly encouraged. Diagnosis of idiopathic pulmonary fibrosis no longer requires surgical lung biopsy; high-resolution computed tomography is an acceptable surrogate. In the context of clinical trials, pathologists are being asked to assign levels of confidence for histologic diagnosis of usual interstitial pneumonia in patients with idiopathic pulmonary fibrosis. Acute exacerbation of idiopathic pulmonary fibrosis is now accepted and should be considered when acute lung injury is superimposed on a background of usual interstitial pneumonia. The updated classification of idiopathic interstitial pneumonias will include a separate category for rare entities, including lymphoid interstitial pneumonia and idiopathic pleuroparenchymal fibroelastosis.
Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
Maurer, Matthew J. , Wellik, Linda, Han, Jing , Özsan, Nazan , Micallef, Ivana N. , Gupta, Mamta , Law, Mark E. , Doǧan, Ahmet , Witzig, Thomas E. , Maurer, Matthew

Mayo Clinic

Blood | September 30, 2012 | Volume: 120 | Issue: 22 | Pages: 4400-4406

10.1182/blood-2012-05-428466 | PMID 23018644 Get It

AbstractSTAT3 regulates cell growth by up-regulating downstream targets, such as Myc. The frequency of phosphorylated STAT3 (pSTAT3) and Myc expression and their prognostic relevance is unknown within diffuse large B-cell lymphoma (DLBCL) germinal center B-cell (GCB) and non-GCB subtypes. pSTAT3 and Myc were studied by immunohistochemistry (IHC) on tumors from 40 DLBCL patients uniformly treated on a clinical trial of epratuzumab/rituximab-CHOP. A total of 35% of cases were pSTAT3-positive, and pSTAT3 positivity was more frequent in the non-GCB (P = .06) type but did not correlate with event-free survival (EFS). Myc expression was observed in 50% of cases and was more frequent in non-GCB type (P = .07). Myc-positive cases had inferior EFS in all patients, including the GCB and pSTAT3-positive cases, were more likely to express Myc (P = .06). Myc translocations involving the major breakpoint regions were found in 10% (3 of 29) of cases, and all 3 cases were GCB and had an inferior EFS (P = .09). pSTAT3, but not Myc expression, was correlated with elevated pretreatment serum cytokines, such as IL-10 (P = .05), G-CSF (P = .03), and TNF-α (P = .04). pSTAT3 IHC in DLBCL tumors has the potential to identify patients for STAT3 pathway–directed therapy; Myc IHC is a potential marker for inferior EFS in GCB patients.
Bid signal pathway components are identified in the temporal cortex with Parkinson disease
Jiang, Hong , Shill, Holly A. , Beach, Thomas G. , Li, Rena , Shen, Yong , He, Ping , Adler, Charles H.

Mayo Clinic

Neurology | September 27, 2012 | Volume: 79 | Issue: 17 | Pages: 1767-1773

10.1212/wnl.0b013e3182703f76 | PMID 23019260 Get It

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Klyuchnikov, Evgeny , Carreras, Jeanette, Armand, Philippe , Bishop, Michael, Bredeson, Christopher , Cairo, Mitchell S. , Fenske, Timothy S. , Freytes, César O. , Gibson, John, Isola, Luis , Inwards, David J. , Laport, Ginna G. , Wiernik, Peter H. , Schouten, Harry C. , Slavin, Shimon, Smith, Sonali M. , Waller, Edmund K. , Hari, Parameswaran , Bacher, Ulrike , Le‐Rademacher, Jennifer , Gale, Robert Peter , Lazarus, Hillard M. , Maziarz, Richard Thomas , Vose, Julie M. , Waller, Edmund K , Hari, Parameswaran

Mayo Clinic

Blood | September 25, 2012 | Volume: 120 | Issue: 20 | Pages: 4256-4262

10.1182/blood-2012-06-436725 | PMID 23007405 Get It

Abstract The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.
CT Grading of Lung Disease in Lymphangioleiomyomatosis
Yao, Jianhua , Taveira‐DaSilva, Angelo M., Colby, Thomas V. , Moss, Joel

Mayo Clinic

American Journal of Roentgenology | September 20, 2012 | Volume: 199 | Issue: 4 | Pages: 787-793

10.2214/ajr.11.7888 | PMID 22997369 Get It

Deconditioning in patients with orthostatic intolerance
Parsaik, Ajay K. , Allison, Thomas G. , Sletten, David M., Benarroch, Eduardo E. , Low, Phillip A. , Sandroni, Paola , Singer, Wolfgang , Joyner, Michael J.

Mayo Clinic

Neurology | September 20, 2012 | Volume: 79 | Issue: 14 | Pages: 1435-1439

10.1212/wnl.0b013e31826d5f95 | PMID 22993288 Get It

Faculty Opinions recommendation of Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Gro
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1088852.541966 Get It

Faculty Opinions recommendation of Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1089765.542900 Get It

Faculty Opinions recommendation of The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1090633.543931 Get It